Attached files
| file | filename |
|---|---|
| 8-K - 8-K - ABBOTT LABORATORIES | a17-11419_18k.htm |
Exhibit 99.1
Abbott Laboratories
Cardiovascular and Neuromodulation
2016 Comparable Sales*
(unaudited)
|
Worldwide |
|
2016 Sales ($ in millions) |
| ||||||||
|
|
|
1Q |
|
2Q |
|
3Q |
|
4Q |
|
FY |
|
|
Rhythm Management |
|
582 |
|
614 |
|
577 |
|
511 |
|
2,284 |
|
|
Electrophysiology |
|
285 |
|
316 |
|
309 |
|
325 |
|
1,235 |
|
|
Heart Failure |
|
154 |
|
159 |
|
148 |
|
152 |
|
613 |
|
|
Vascular |
|
697 |
|
788 |
|
719 |
|
730 |
|
2,934 |
|
|
Structural Heart |
|
224 |
|
249 |
|
239 |
|
251 |
|
963 |
|
|
Neuromodulation |
|
116 |
|
140 |
|
141 |
|
167 |
|
564 |
|
|
Total Cardiovascular and Neuromodulation |
|
2,058 |
|
2,266 |
|
2,133 |
|
2,136 |
|
8,593 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S. |
|
2016 Sales ($ in millions) |
| ||||||||
|
|
|
1Q |
|
2Q |
|
3Q |
|
4Q |
|
FY |
|
|
Rhythm Management |
|
317 |
|
315 |
|
297 |
|
233 |
|
1,162 |
|
|
Electrophysiology |
|
132 |
|
137 |
|
136 |
|
139 |
|
544 |
|
|
Heart Failure |
|
121 |
|
122 |
|
118 |
|
116 |
|
477 |
|
|
Vascular |
|
281 |
|
331 |
|
294 |
|
291 |
|
1,197 |
|
|
Structural Heart |
|
87 |
|
96 |
|
96 |
|
97 |
|
376 |
|
|
Neuromodulation |
|
84 |
|
97 |
|
106 |
|
127 |
|
414 |
|
|
Total Cardiovascular and Neuromodulation |
|
1,022 |
|
1,098 |
|
1,047 |
|
1,003 |
|
4,170 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
International |
|
2016 Sales ($ in millions) |
| ||||||||
|
|
|
1Q |
|
2Q |
|
3Q |
|
4Q |
|
FY |
|
|
Rhythm Management |
|
265 |
|
299 |
|
280 |
|
278 |
|
1,122 |
|
|
Electrophysiology |
|
153 |
|
179 |
|
173 |
|
186 |
|
691 |
|
|
Heart Failure |
|
33 |
|
37 |
|
30 |
|
36 |
|
136 |
|
|
Vascular |
|
416 |
|
457 |
|
425 |
|
439 |
|
1,737 |
|
|
Structural Heart |
|
137 |
|
153 |
|
143 |
|
154 |
|
587 |
|
|
Neuromodulation |
|
32 |
|
43 |
|
35 |
|
40 |
|
150 |
|
|
Total Cardiovascular and Neuromodulation |
|
1,036 |
|
1,168 |
|
1,086 |
|
1,133 |
|
4,423 |
|
* Abbott’s cardiovascular and neuromodulation (ACN) business includes its historical Vascular Products segment and the businesses of St. Jude Medical, LLC. St. Jude Medical’s vascular closure business has been removed from all periods presented above given the divestiture of this business. Administrative fees paid by St. Jude Medical to group purchasing organizations have been reclassified from the Selling, general and administrative line in St. Jude Medical’s historical financial statements and are included as a reduction to revenue to conform to Abbott’s presentation. Abbott completed its acquisition of St. Jude Medical, Inc. (now St. Jude Medical, LLC) on January 4, 2017.